Disc Medicine Cuts 20% of Staff After Key Drug Fails Accelerated FDA Approval
Summary
Disc Medicine announced a significant workforce reduction of approximately 20%, impacting about 31 employees, following the FDA's denial of accelerated approval for its bitopertin treatment. The company expects to incur about $2 million in charges, primarily for severance, mostly in the first quarter. This restructuring is a direct strategic response to the FDA's Complete Response Letter for bitopertin, which was previously disclosed on February 17th. While the FDA setback was known, the substantial workforce reduction is new and signals a material operational realignment and cost-cutting effort. Investors will now focus on the company's ability to manage its remaining pipeline and the upcoming topline data from the bitopertin Phase 3 study, expected in the fourth quarter, which could support traditional approval.
At the time of this announcement, IRON was trading at $66.62 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.5B. The 52-week trading range was $30.82 to $99.50. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.